---
schema_version: "secwatch.filing_event.v1"
accession: "0001730463-24-000021"
form_type: "8-K"
ticker: "AUTL"
cik: "0001730463"
company_name: "Autolus Therapeutics plc"
filed_at: "2024-03-14T23:59:59+00:00"
generated_at: "2026-06-04T19:53:38.367997+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Autolus FY2023 net loss $208.4M; raises $600M via BioNTech deal and offering; CDO resigns

## Summary
- Net loss for FY2023 was $208.4M ($1.20 diluted EPS) vs $148.8M in 2022; cash at year-end $239.6M.
- In Feb 2024, closed BioNTech collaboration ($250M upfront) and $350M ADS offering for $600M gross proceeds to fund obe-cel launch.
- BLA for obe-cel in r/r adult B-ALL submitted to FDA; PDUFA target action date Nov 16, 2024; MAA submitted to EMA.
- CDO Dr. Edgar Braendle resigns effective March 2024; will consult. Chris Williams promoted to CBO, Alex Driggs to SVP Legal.
- Obe-cel Phase 1 SLE trial open for enrollment; initial data expected late 2024; Nucleus manufacturing facility obtained MIA for commercial supply.

## SEC filing metadata
- accession: 0001730463-24-000021
- form_type: 8-K
- ticker: AUTL
- cik: 0001730463
- company_name: Autolus Therapeutics plc
- filed_at: 2024-03-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1730463/000173046324000021/0001730463-24-000021-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1730463/000173046324000021/autl-20240314.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001730463-24-000021
- JSON: https://secwatch.observer/filing/0001730463-24-000021.json
- Plain text: https://secwatch.observer/filing/0001730463-24-000021.txt

## Key facts
- Earnings Releases
  Autolus Therapeutics plc reported financial results for the full year ended December 31, 2023.
  - Period: the full year ended December 31, 2023
  - Result: reported results
  source text: On March 14, 2024, Autolus Therapeutics plc (the “ Company ”) issued a press release announcing its recent business highlights and financial results for year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1730463/000173046324000021/0001730463-24-000021-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.